{"id":"placebo-matching-ribavirin","safety":{"commonSideEffects":[{"rate":null,"effect":"No adverse events expected (placebo)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ribavirin is a guanosine analog that interferes with viral replication by inhibiting inosine monophosphate dehydrogenase and depleting guanosine nucleotides, thereby reducing viral RNA synthesis. As a placebo matching formulation, this product is used in clinical trials to maintain blinding while controlling for the effects of ribavirin itself. The placebo is designed to be indistinguishable from active ribavirin in appearance and administration.","oneSentence":"This is a placebo control matching the appearance and dosing schedule of ribavirin, an antiviral nucleoside analog that inhibits viral RNA synthesis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:28:03.569Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Placebo control in phase 3 clinical trials for viral infections (specific indication dependent on trial design)"}]},"trialDetails":[{"nctId":"NCT01425203","phase":"PHASE3","title":"The Effect of Boceprevir in Russian Participants Diagnosed With Chronic Hepatitis C Genotype 1 (P08160)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-11-23","conditions":"Chronic Hepatitis C Genotype 1","enrollment":238},{"nctId":"NCT01710501","phase":"PHASE2","title":"A Study of Different Doses of Grazoprevir (MK-5172) Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-12-07","conditions":"Chronic Hepatitis C (CHC)","enrollment":87},{"nctId":"NCT01965535","phase":"PHASE2","title":"Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin in Cirrhotic Subjects With Chronic Genotype 1 HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-10","conditions":"HCV Infection","enrollment":155},{"nctId":"NCT00704184","phase":"PHASE2","title":"Safety and Efficacy of Vaniprevir (MK7009) Administered With Pegylated-Interferon and Ribavirin (MK-7009-007)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-07-25","conditions":"Hepatitis C","enrollment":95},{"nctId":"NCT00704405","phase":"PHASE2","title":"Safety and Efficacy of Vaniprevir (MK-7009) With Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) in Treatment-Experienced Hepatitis C Virus (HCV) Participants (MK-7009-009)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-03-27","conditions":"Hepatitis C, Chronic","enrollment":285},{"nctId":"NCT01314261","phase":"PHASE2","title":"Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected Subjects","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2011-03","conditions":"Chronic Hepatitis C, Hepatitis C Virus (HCV) Infection","enrollment":37},{"nctId":"NCT00851890","phase":"PHASE2","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2009-03","conditions":"Chronic Hepatitis C Virus Infection","enrollment":30},{"nctId":"NCT01439373","phase":"PHASE2","title":"Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-07-07","conditions":"Hepatitis C, Chronic","enrollment":16},{"nctId":"NCT01482390","phase":"PHASE2","title":"A Study of Mericitabine in Combination With Telaprevir and Peginterferon Alfa-2a / Ribavirin in Participants With Chronic Hepatitis C","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-11-30","conditions":"Hepatitis C","enrollment":80},{"nctId":"NCT00845065","phase":"PHASE3","title":"Boceprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05685AM2)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-02","conditions":"Hepatitis C, Chronic","enrollment":202},{"nctId":"NCT01470651","phase":"PHASE4","title":"Armodafinil for Patients Starting Hepatitis C Virus Treatment","status":"TERMINATED","sponsor":"Research Foundation for Mental Hygiene, Inc.","startDate":"2011-10","conditions":"Hepatitis C","enrollment":26},{"nctId":"NCT02716779","phase":"PHASE2","title":"Influence of Ribavirin on the Initial Virological Response in Treatment Naïve Patients With Hepatitis C Genotype 1 Infection","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-04","conditions":"Hepatitis C, Chronic","enrollment":68},{"nctId":"NCT01425970","phase":"PHASE2","title":"Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2012-05","conditions":"Hepatitis C","enrollment":210},{"nctId":"NCT01448044","phase":"PHASE3","title":"Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-12","conditions":"Hepatitis C","enrollment":152},{"nctId":"NCT01616524","phase":"PHASE3","title":"Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-07","conditions":"Hepatitis C Virus (HCV)","enrollment":880},{"nctId":"NCT01973049","phase":"PHASE3","title":"UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-12","conditions":"Hepatitis C","enrollment":202},{"nctId":"NCT01725529","phase":"PHASE3","title":"An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepatitis C-Infected Patients","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2012-11","conditions":"Hepatitis C, Chronic","enrollment":457},{"nctId":"NCT01852604","phase":"PHASE2","title":"Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-03","conditions":"Chronic Hepatitis C Virus","enrollment":143},{"nctId":"NCT01371604","phase":"PHASE2","title":"Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks (MK-2355-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-07","conditions":"Hepatitis C, Chronic","enrollment":68},{"nctId":"NCT01074008","phase":"PHASE2","title":"A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-03","conditions":"Hepatitis C, HCV, Chronic Hepatitis C Infection","enrollment":74},{"nctId":"NCT01682720","phase":"PHASE3","title":"Sofosbuvir and Ribavirin in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-09","conditions":"Hepatitis C","enrollment":421},{"nctId":"NCT00627926","phase":"PHASE3","title":"A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2008-03","conditions":"Hepatitis C","enrollment":1095},{"nctId":"NCT00420784","phase":"PHASE2","title":"A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2007-02","conditions":"Hepatitis C","enrollment":465},{"nctId":"NCT00372385","phase":"PHASE2","title":"Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis C","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2006-08","conditions":"Chronic Hepatitis C","enrollment":334},{"nctId":"NCT00336479","phase":"PHASE2","title":"Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2006-06","conditions":"Chronic Hepatitis C","enrollment":263},{"nctId":"NCT02150291","phase":"PHASE4","title":"A Pilot Study to Assess the Efficacy and Safety of Folic Acid and/or Vitamin B Complex on Hepatitis C Infected Patients Treated With Pegylated Interferon and Ribavirin.","status":"UNKNOWN","sponsor":"British University In Egypt","startDate":"2014-05","conditions":"Hepatitis C","enrollment":120},{"nctId":"NCT01604850","phase":"PHASE3","title":"Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION)","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-06","conditions":"Chronic Hepatitis C","enrollment":202},{"nctId":"NCT01542788","phase":"PHASE3","title":"Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-03","conditions":"Chronic Hepatitis C","enrollment":278},{"nctId":"NCT01188772","phase":"PHASE2","title":"Sofosbuvir in Combination With Pegylated Interferon and Ribavirin and in Treatment-Naive Hepatitis C-infected Patients","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-08","conditions":"Hepatitis C Virus","enrollment":147},{"nctId":"NCT01054729","phase":"PHASE2","title":"Dose-Ranging Study of Sofosbuvir in Combination With Pegylated Interferon and Ribavirin in Treatment Naïve GT 1 HCV Patients","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-01","conditions":"Hepatitis C","enrollment":64},{"nctId":"NCT00911963","phase":"PHASE1, PHASE2","title":"Pharmacokinetics of Multiple Ascending Doses of VCH-222 in Subjects With Chronic Hepatitis C Infection","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2009-04","conditions":"Hepatitis C","enrollment":49},{"nctId":"NCT01435044","phase":"PHASE2","title":"Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-09","conditions":"Hepatitis C, Chronic","enrollment":239},{"nctId":"NCT01271790","phase":"PHASE2","title":"A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-10","conditions":"Hepatitis C, Chronic","enrollment":245},{"nctId":"NCT01356160","phase":"PHASE2","title":"GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-07","conditions":"Hepatitis C, Chronic","enrollment":351},{"nctId":"NCT01225380","phase":"PHASE2","title":"A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-10","conditions":"Chronic Hepatitis C Infection","enrollment":324},{"nctId":"NCT00703118","phase":"PHASE3","title":"A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment","status":"COMPLETED","sponsor":"Tibotec BVBA","startDate":"2008-10","conditions":"Hepatitis C, Chronic","enrollment":663},{"nctId":"NCT01434498","phase":"PHASE2","title":"GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-09","conditions":"Chronic Genotype 1a or 1b HCV Infection","enrollment":163},{"nctId":"NCT01435226","phase":"PHASE2","title":"GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-09","conditions":"Hepatitis C, Chronic","enrollment":170},{"nctId":"NCT02008214","phase":"PHASE4","title":"Efficacy of PTX+IFN Alpha+ RBV on Hepatitis C Virus Coinfected HIV Patients","status":"UNKNOWN","sponsor":"Centro Universitario de Ciencias de la Salud, Mexico","startDate":"2013-12","conditions":"Hepacivirus, HIV Infections","enrollment":60},{"nctId":"NCT01797848","phase":"PHASE3","title":"Efficacy and Safety Evaluation of a Treatment Consisting of Peg Interferon Alfa + Ribavirin + Daclatasvir in HCV Genotype 1 and 4 Treatment naïve Patients","status":"WITHDRAWN","sponsor":"Bristol-Myers Squibb","startDate":"2014-06","conditions":"Hepatitis C","enrollment":""},{"nctId":"NCT00529568","phase":"PHASE3","title":"Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-10","conditions":"Hepatitis C, Chronic","enrollment":759},{"nctId":"NCT00516321","phase":"PHASE3","title":"Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Subjects With Hepatitis C Related Liver Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-10","conditions":"Hepatitis C, Chronic","enrollment":687},{"nctId":"NCT00983853","phase":"PHASE2","title":"Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2009-10","conditions":"Hepatitis C, HIV Infections","enrollment":62},{"nctId":"NCT00580801","phase":"PHASE2","title":"An Exploratory Study of Telaprevir in Treatment-Naive Participants With Chronic Genotype 4 Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"Tibotec BVBA","startDate":"2008-01","conditions":"Hepatitis C","enrollment":24},{"nctId":"NCT00249860","phase":"PHASE3","title":"A Multicenter Phase 3 Study of Interferon-beta-1a for the Treatment of Chronic Hepatitis C in Asian Subjects","status":"COMPLETED","sponsor":"EMD Serono","startDate":"2002-09","conditions":"Hepatitis C","enrollment":257},{"nctId":"NCT00561015","phase":"PHASE2","title":"A Phase 2a Study to Evaluate Viral Kinetics and Safety of Telaprevir in Participants With Genotype 2 or 3 Hepatitis C Infection","status":"COMPLETED","sponsor":"Tibotec BVBA","startDate":"2007-12","conditions":"Hepatitis C, Chronic","enrollment":52},{"nctId":"NCT01250366","phase":"PHASE1","title":"Study of the Safety & PK of INX-08189 in Chronically-infected HCV, Treatment-naïve Subjects","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-10","conditions":"HCV (Genotype 1)","enrollment":70}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":17,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo matching Ribavirin","genericName":"Placebo matching Ribavirin","companyName":"Bristol-Myers Squibb","companyId":"bristol-myers-squibb","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a placebo control matching the appearance and dosing schedule of ribavirin, an antiviral nucleoside analog that inhibits viral RNA synthesis. Used for Placebo control in phase 3 clinical trials for viral infections (specific indication dependent on trial design).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}